source
- Tango’s pancreatic cancer combo shows striking promise at ESMO, building on Revolution Medicines’ earlier successTango presented new data on its pancreatic cancer combination at the opening of the ESMO conference, highlighting a striking level of activity that builds on earlier success reported by Revolution…
- Tango Therapeutics reports 82% response rate for vopimetostat plus Rasonque in pancreatic cancer, down from 92% earlierTango Therapeutics announced updated data from its ongoing Phase 1/2 trial combining its PRMT5 inhibitor vopimetostat with Revolution Medicines' newly approved drug Rasonque (daraxonrasib) in secon…BioSpace · 18d agoNegative readoutNegative